636 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This case report highlights a critical, albeit rare, adverse event associated with rapid weight loss induced by GLP-1 receptor agonists in patients with cardiac implantable electronic devices (CIEDs). The finding sugg…
These preliminary findings are highly significant as they suggest semaglutide could be a viable pharmacologic option for adolescents battling MASLD, a condition currently lacking approved treatments. The observed impr…
Understanding GLP-1's direct vascular effects could significantly expand its therapeutic potential beyond mere glucose control, offering new avenues for patient care. If GLP-1 or its analogues demonstrate independent …
Incretin-based therapies represent a highly promising and multifaceted approach in hypertension management, uniquely combining significant metabolic and cardiovascular benefits. Their ability to reduce blood pressure,…
This study addresses a crucial gap in managing obesity post-GLP-1 agonist therapy, which has significant implications for patient care and public health. If gradual withdrawal proves superior, it could establish a new…
Obesity-related HFpEF is a major public health challenge with few targeted treatments, making the potential of Tirzepatide highly significant. If this study successfully identifies the mechanisms by which Tirzepatide …
This study highlights the critical importance of timing when discontinuing GLP-1RA/tirzepatide before pregnancy to mitigate gestational diabetes risk. While longer discontinuation periods appear safe, abrupt cessation…
This case report highlights a critical potential adverse effect of GLP-1 RAs on mood and behavior, particularly in vulnerable populations such as those with pre-existing Major Depressive Disorder. Given that GLP-1 rec…
The potential for a therapeutic strategy that not only achieves significant weight loss but also preserves crucial muscle mass and bone health would be a major advancement in obesity management. Current weight loss ap…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
The review highlights that GLP-1 RAs are highly effective for weight management and glycemic control, offering significant benefits for women with conditions like polycystic ovary syndrome (PCOS) or those at elevated …
This case highlights the critical importance of vigilant monitoring of thyroid function in post-thyroidectomy patients initiating tirzepatide or similar incretin-based medications. The significant weight loss and pote…
This study is significant because it sought to directly investigate the anti-inflammatory and chondroprotective (cartilage-protecting) potential of liraglutide, a GLP-1 receptor agonist, in knee osteoarthritis beyond …
The progressive decline of beta-cell function is a hallmark of Type 2 Diabetes Mellitus (T2DM), often leading to increased insulin dependence and uncontrolled blood sugar. If liraglutide were shown to preserve beta-ce…
This study is significant because it addresses a critical unmet need for effective and manageable weight loss interventions in a highly complex and often overlooked patient population. The successful completion of the…
The persistent cognitive dysfunction in Major Depressive Disorder (MDD) represents a significant burden for patients, often not adequately addressed by standard antidepressants. Semaglutide, a GLP-1 receptor agonist (…
This study is significant because it explores a novel application of GLP-1 receptor agonists beyond their established roles in diabetes and obesity, potentially positioning them as tools for proactive health optimizat…
This research is significant because it investigates a potential new benefit of tirzepatide beyond weight management and metabolic improvement: reducing breast cancer risk. Given the strong link between obesity and br…
Understanding how GLP-1RAs and GIP/GLP-1-dual agonists affect ocular blood flow and retinal health is critically important given their widespread use in diabetes management. If these medications demonstrate a benefici…
The introduction of resmetirom and the proven efficacy of semaglutide represent a revolutionary shift in the treatment paradigm for MASH, moving beyond solely lifestyle interventions. These drugs offer the first speci…
The withdrawal of this trial highlights the challenges in conducting long-term comparative studies on established diabetes treatments. While this specific study yielded no results, the underlying question of how diffe…
If liraglutide proves effective in improving lung function, it would represent a significant pleiotropic benefit beyond its established role in glucose control and weight management for Type 2 Diabetes Mellitus patien…
This study is critically important because it addresses a significant unmet medical need for effective treatments for cognitive dysfunction in individuals with type 2 diabetes, a population at high risk for dementia. …
Obstructive sleep apnoea significantly impacts quality of life and carries substantial health risks, particularly in obese populations. Liraglutide, a GLP-1 analogue, is already approved for weight management and type…
This multicentre, non-interventional study provides invaluable real-world evidence on Liraglutide (Saxenda®) safety and effectiveness, which is critical for understanding its performance outside of controlled clinical…
If the collected data demonstrates positive outcomes, this study could establish liraglutide, a GLP-1 receptor agonist, as a novel neuroprotective treatment for diabetic neuropathy. This would be a significant advance…
This trial design is significant because chronic heart failure and type 2 diabetes represent a substantial global health burden, and understanding how GLP-1 (glucagon-like peptide-1) agonists impact cardiac function c…
This study highlights the potential for IDegLira to significantly improve the quality of life for very old patients with Type 2 Diabetes by streamlining their treatment. Simplifying medication regimens can enhance adh…
This Phase 3 trial is a critical step in evaluating CagriSema as a potentially more potent treatment for obesity and type 2 diabetes than current GLP-1 monotherapies. The large enrollment of 2500 participants and exte…
This research is crucial as it expands the understanding of GLP-1 RA efficacy beyond weight-centric applications, particularly for a patient population where weight loss might not be a primary goal or even desirable. …
A successful semaglutide nasal spray could offer a more convenient and potentially less invasive administration route for patients managing overweight or obesity. This novel delivery method could significantly improve…
Reducing NETosis could represent a novel therapeutic strategy for managing inflammation and progression in diabetic kidney disease and immune-mediated kidney diseases. Identifying specific drug classes like SGLT2 inhi…
This research is crucial for understanding the precise behavioral mechanisms through which GLP-1 receptor agonists promote weight loss, moving beyond self-reported data to direct observation. The identification of spe…